Ligand Pharmaceuticals LGND Long-term contingent liabilities
Long-term contingent liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:LiabilityForContingentValueRights.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's long-term contingent liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's long-term contingent liabilities?
- Ligand Pharmaceuticals (LGND) reported long-term contingent liabilities of $3.5M in Q1 2026.
- How has Ligand Pharmaceuticals's long-term contingent liabilities changed year-over-year?
- Ligand Pharmaceuticals's long-term contingent liabilities decreased by 13.1% year-over-year, from $4.03M to $3.5M.
- What is the long-term trend for Ligand Pharmaceuticals's long-term contingent liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's long-term contingent liabilities has grown at a -20.5% compound annual growth rate (CAGR), from $9.25M to $2.93M.
- What does long-term contingent liabilities mean?
- This represents the long-term financial obligation to pay out contingent value rights or similar performance-based payments to third parties. These liabilities are typically tied to the future success or regulatory milestones of specific drug development programs. It serves as a measure of the company's long-term financial commitments resulting from strategic business development activities.